Research and Development Expenses Breakdown: Pharming Group N.V. vs Lantheus Holdings, Inc.

Pharma R&D: A Decade of Strategic Investment

__timestampLantheus Holdings, Inc.Pharming Group N.V.
Wednesday, January 1, 20141367300014182353
Thursday, January 1, 20151435800015503028
Friday, January 1, 20161220300016183585
Sunday, January 1, 20171812500022382849
Monday, January 1, 20181707100033038206
Tuesday, January 1, 20192001800031777040
Wednesday, January 1, 20203278800041464134
Friday, January 1, 20214496600067178053
Saturday, January 1, 202231168100052531000
Sunday, January 1, 20237770700068914000
Loading chart...

Infusing magic into the data realm

A Decade of Innovation: R&D Spending in the Pharmaceutical Sector

In the ever-evolving landscape of pharmaceuticals, research and development (R&D) expenses are a critical indicator of innovation and growth. Over the past decade, Lantheus Holdings, Inc. and Pharming Group N.V. have demonstrated significant investment in R&D, reflecting their commitment to advancing medical science. From 2014 to 2023, Lantheus Holdings, Inc. saw a remarkable increase in R&D spending, peaking in 2022 with a 1,200% rise compared to 2014. Meanwhile, Pharming Group N.V. maintained a steady growth trajectory, with a notable 385% increase in the same period. This trend underscores the competitive nature of the industry, where strategic investments in R&D can lead to groundbreaking treatments and therapies. As these companies continue to innovate, their R&D expenditures serve as a testament to their dedication to improving global health outcomes.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025